EFFECT OF EDUCATIONAL AND POLICY INTERVENTIONS ON INSTITUTIONAL UTILIZATION OF WET NEBULIZATION RESPIRATORY DRUGS AND PORTABLE INHALERS
Main Article Content
Keywords
Respiratory drug therapy, wet nebulization, portable inhaler, drug utilization, educational intervention, time-series analysis
Abstract
Background
Asthma and chronic obstructive pulmonary disease treatment guidelines support the preferential use of portable inhalers (PIs) over wet nebulization (WN) respiratory therapy. Hospital- and community-based educational initiatives and a community-based provincial drug program policy change were previously implemented to promote the conversion of WN therapy to PI and spacer device use in Nova Scotia.
Objective
To examine the effect of these interventions on salbutamol, ipratropium bromide, and spacer device (Aerochamber®) use at the Queen Elizabeth II Health Sciences Centre (QEII HSC).
Methods
We conducted a time-series analysis of drug utilization data from August 1998 to July 2005. We used two intervention phases compared to the pre-intervention phase to determine whether the educational and policy interventions were associated with significant changes in monthly drug and spacer device utilization rates at the QEII HSC (1000-bed teaching hospital; Halifax, Nova Scotia).
Results
Salbutamol and ipratropium bromide PI use significantly increased in both intervention phases, compared to the pre-intervention phase. Mean (SD) defined daily doses/100 bed-days for salbutamol PI increased from 30.4 (0.4) in the pre-intervention phase to 34.6 (0.9) and 37.0 (0.4) in intervention phases I and II respectively (p<0.001 for both), and ipratropium bromide PI increased from 27.3 (3.5) to 32.8 (2.5) in intervention phase I (p=0.004) and 35.6 (3.5) in intervention phase II (p<0.001). However, a significant corresponding decrease was observed with salbutamol WN only. Mean (SD) Aerochamber® units/100 bed-days significantly increased.
Conclusions
Educational and policy interventions had limited effects on converting WN to PI use at the QEII HSC.
References
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2007.http://www.goldcopd.org . (Accessed 9 Apr 2008).
3. National Heart, Lung, and Blood Institute. Morbidity and mortality: 2007 chart book on cardiovascular, lung, and blood diseases. Bethesda, Maryland: National Heart, Lung, and Blood Institute, June 2007. http://www.nhlbi.nih.gov/resources/docs/07- chtbk.pdf (Accessed 9 Apr 2008).
4. Health Canada. Economic burden of illness in Canada, 1998. Ottawa, Ca nada: Health Canada, 2002.
5. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-- 2003. Can Respir J 2003;10 Suppl A:11A-65A.
6. Boulet LP, Becker A, Berube D, Beveridge R, Ernst P. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 1999;161:S1- 61.
7. Becker A, Lemiere C, Berube D, et al. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003.CMAJ 2005;173:S3-11.
8. Beveridge RC, Grunfeld AF, Hodder RV, Verbeek PR. Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society. CMAJ 1996;155:25- 37.
9. Dolovic h MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127:335- 71.
10. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta- agonist treatment of acute asthma. Cochrane Database Syst Rev 2006:CD000052.
11. Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 1997;157:1736-44.
12. Newman KB, Milne S, Hamilton C, Hall K. A comparison of albuterol administered by metered -dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. Chest 2002;121:1036-41.
13. Turner MO, Gafni A, Swan D, FitzGerald JM. A review and economic evaluation of bronchodilator delivery methods in hospitalized patients. Arch Intern Med 1996;156:2113-8.
14. Jasper AC, Mohsenifar Z, Kahan S, Goldberg HS, Koerner SK. Cost-benefit comparison of aerosol bronchodilator delivery methods in hospitalized patients. Chest 1987;91:614- 8.
15. Bowton DL, Goldsmith WM, Haponik EF. Substitution of metered-dose inhalers for hand - held nebulizers. Success and cost savings in a large, acute- care hospital. Chest 1992;101:305-8.
16. Estivariz CF, Bhatti LI, Pati R, et al. An outbreak of Burkholderia cepacia associated with contamination of albuterol and nasal spray. Chest 2006;130:1346-53.
17. McLean- Veysey PR, Kelly KD. The role of nebulization solutions in obstructive lung disease. Provincial Drug Evaluation Program Bulletin 1997;4:7- 14.
18. Murphy AL, MacKinnon NJ, Flanagan PS, Bowles SK, Sketris IS. Pharmacists' participation in an inhaled respiratory
19. Kephart G, Sketris IS, Bowles SK, Richard ME, Cooke CA. Impact of a criteria-based reimbursement policy on the use of respiratory drugs delivered by nebulizer and health care services utilization in Nova Scotia, Canada. Pharmacotherapy 2005;25:1248-57.
20. Capital Health. About Us. http://www.cdha.nshealth.ca/default.aspx?Page= CoreSubPage&category.Categories.1=351¢ erContent.Id.0=5829. (Accessed 9 Apr 2008).
21. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2005. Oslo, Norway: World Health Organization, 2005. http://www.whocc.no/atcddd/. (Accessed 9 Apr 2008).
22. Sketris IS, Metge C, Blackburn J, et al. A Canadian Guide for Drug Utilization Studies using Administrative Pharmacy Claims Data: Focus on the WHO ATC System and Defined Daily Dose. Halifax, Canada: Dalhousie University, 2001.
23. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-87.
24. Box GEP, Jenkins GM, Reinsel GC. Time Series Analysis: Forecasting and Control. 3rd ed. San Francisco, U.S.A.: Holden-Day, 1994.
25. Box GEP, Tiao GC. Intervention analysis with applications to economic and environmental problems. Journal of the American Statistical Association 1975;70:70-79.
26. Hirsch RM, Slack JR, Smith RA. Techniques for trend assessment for monthly water quality data. Water Resources Research 1982;18:107-121.
27. Hendeles L, Hatton RC, Coons TJ, Carlson L. Automatic replacement of albuterol nebulizer therapy by metered -dose inhaler and valved holding chamber. Am J Health Syst Pharm 2005;62:1053- 61.
28. Bowles SK, Sketris I, Kephart G. Use of wet nebulized inhaled respiratory medications under criteria-based reimbursement guidelines in a publicly funded Seniors' Pharmacare Program in Nova Scotia, Canada. Am J Geriatr Pharmacother 2007;5:120-8.
29. Hurley KF, Sargeant J, Duffy J, Sketris I, Sinclair D, Ducharme J. Perceptual reasons for resistance to change in the emergency department use of holding chambers for children with asthma. Ann Emerg Med 2008;51:70 -7.
30. Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001;39:II-2- II-45.
31. Davis DA, Thomson MA, Oxman AD, Haynes RB. Changing physician performance. A systematic review of the effect of continuing medical education strategies. JAMA 1995;274:700- 5.
32. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004;8:iii-iv, 1- 72.
33, Gilbody S, Whitty P, Grimshaw J, Thomas R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA 2003;289:3145-51.
34. Bosch M, van der Weijden T, Wensing M, Grol R. Tailoring quality improvement interventions to identified barriers: a multiple case analysis. J Eval Clin Pract 2007;13:161- 8.
35. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299-309.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.